Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888232 | 0.89 | ENPP1 (0.51) | ENPP1P2RY1POLBADORA3ADORA2A | |
| SCHEMBL888084 | 0.86 | POLB (0.47) | ENPP1P2RY1POLB | |
| SCHEMBL888141 | 0.83 | ENPP1 (0.58) | ENPP1P2RY1POLBADORA3ADORA2A | |
| SCHEMBL887961 | 0.81 | ENPP1 (0.43) | ENPP1P2RY1POLBSLC29A1DTYMK | |
| SCHEMBL888235 | 0.80 | TAS1R3 (0.49) | POLBADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1140765 | 0.80 | POLB (0.56) | ENPP1P2RY1POLBDTYMKHIF1A | |
| SCHEMBL888072 | 0.79 | POLB (0.51) | POLB | |
| SCHEMBL6910499 | 0.78 | TYMP (0.57) | ENPP1P2RY1POLBADORA3ADORA2A | |
| SCHEMBL12570175 | 0.77 | SLC29A1 (0.61) | SLC29A1HIF1A | |
| SCHEMBL889556 | 0.77 | SLC29A1 (0.61) | SLC29A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | ENPP1 170/4885P2RY1 873/4885POLB 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.